Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Are phase I trials safe for older patients?

Baldini C, Le Saux O, Helissey C, Aspeslagh S, Castanon E, Varga A, Gazzah A, Bahleda R, Mir O, Massard C, Soria JC, Hollebecque A.

J Geriatr Oncol. 2018 Mar;9(2):87-92. doi: 10.1016/j.jgo.2017.08.012. Epub 2017 Sep 8. Review.

PMID:
28890328
2.

Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.

Bautista F, Moreno L, Marshall L, Pearson ADJ, Geoerger B, Paoletti X.

Eur J Cancer. 2017 Nov;86:275-284. doi: 10.1016/j.ejca.2017.09.015. Epub 2017 Oct 19.

PMID:
29055843
3.

Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy.

Lichtman SM, Boparai MK.

Curr Treat Options Oncol. 2008 Jun;9(2-3):191-203. doi: 10.1007/s11864-008-0060-6. Epub 2008 Jul 29. Review.

PMID:
18663583
4.

Geriatric oncology and clinical trials.

Lichtman SM.

Am Soc Clin Oncol Educ Book. 2015:e127-31. doi: 10.14694/EdBook_AM.2015.35.e127.

5.

Comprehensive Geriatric Assessment in the Older Adult with Cancer: A Review.

Hernandez Torres C, Hsu T.

Eur Urol Focus. 2017 Oct;3(4-5):330-339. doi: 10.1016/j.euf.2017.10.010. Epub 2018 Jan 10. Review.

PMID:
29331624
6.

Is my older cancer patient on too many medications?

Turner JP, Shakib S, Bell JS.

J Geriatr Oncol. 2017 Mar;8(2):77-81. doi: 10.1016/j.jgo.2016.10.003. Epub 2016 Nov 11. Review.

PMID:
27840102
7.

Competing Risks in Older Patients With Cancer: A Systematic Review of Geriatric Oncology Trials.

Burdett N, Vincent AD, O'Callaghan M, Kichenadasse G.

J Natl Cancer Inst. 2018 Aug 1;110(8):825-830. doi: 10.1093/jnci/djy111.

PMID:
30011032
8.

Polypharmacy and potentially inappropriate medication use in geriatric oncology.

Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM.

J Geriatr Oncol. 2016 Sep;7(5):346-53. doi: 10.1016/j.jgo.2016.07.010. Epub 2016 Aug 3. Review.

9.

Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations.

Hurria A, Dale W, Mooney M, Rowland JH, Ballman KV, Cohen HJ, Muss HB, Schilsky RL, Ferrell B, Extermann M, Schmader KE, Mohile SG; Cancer and Aging Research Group.

J Clin Oncol. 2014 Aug 20;32(24):2587-94. Review.

10.

End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article.

Wildiers H, Mauer M, Pallis A, Hurria A, Mohile SG, Luciani A, Curigliano G, Extermann M, Lichtman SM, Ballman K, Cohen HJ, Muss H, Wedding U.

J Clin Oncol. 2013 Oct 10;31(29):3711-8. doi: 10.1200/JCO.2013.49.6125. Epub 2013 Sep 9.

PMID:
24019549
11.

Polypharmacy in the Geriatric Oncology Population.

Hersh LR, Beldowski K, Hajjar ER.

Curr Oncol Rep. 2017 Sep 23;19(11):73. doi: 10.1007/s11912-017-0632-3. Review.

PMID:
28942563
12.

Dose escalation methods in phase I cancer clinical trials.

Le Tourneau C, Lee JJ, Siu LL.

J Natl Cancer Inst. 2009 May 20;101(10):708-20. doi: 10.1093/jnci/djp079. Epub 2009 May 12. Review.

13.

The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.

van Brummelen EM, Huitema AD, van Werkhoven E, Beijnen JH, Schellens JH.

J Pharmacokinet Pharmacodyn. 2016 Jun;43(3):235-42. doi: 10.1007/s10928-016-9466-0. Epub 2016 Mar 10. Review.

PMID:
26960536
14.

How do oncologists make decisions about chemotherapy for their older patients with cancer? A survey of Australian oncologists.

Moth EB, Kiely BE, Naganathan V, Martin A, Blinman P.

Support Care Cancer. 2018 Feb;26(2):451-460. doi: 10.1007/s00520-017-3843-0. Epub 2017 Aug 3.

PMID:
28776149
15.

[Geriatric assessment and prognostic scores in older cancer patient: Additional support to the therapeutic decision?]

Pamoukdjian F, Liuu E, Caillet P, Gisselbrecht M, Herbaud S, Boudou-Rouquette P, Zelek L, Paillaud E.

Bull Cancer. 2017 Nov;104(11):946-955. doi: 10.1016/j.bulcan.2017.10.004. Epub 2017 Nov 14. Review. French.

PMID:
29150094
16.

Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs.

Jardim DL, Hess KR, Lorusso P, Kurzrock R, Hong DS.

Clin Cancer Res. 2014 Jan 15;20(2):281-8. doi: 10.1158/1078-0432.CCR-13-2103. Epub 2013 Nov 4.

17.

Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials.

Hirakawa A, Yonemori K, Kinoshita F, Kobayashi Y, Okuma HS, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Harris PJ, Takebe N.

Cancer Sci. 2018 Jan;109(1):207-214. doi: 10.1111/cas.13436. Epub 2017 Dec 8.

18.

Evaluating the role of phase I expansion cohorts in oncologic drug development.

Norris RE, Behtaj M, Fu P, Dowlati A.

Invest New Drugs. 2017 Feb;35(1):108-114. doi: 10.1007/s10637-016-0394-z. Epub 2016 Oct 7. Review.

PMID:
27718038
19.

Immune Checkpoint Inhibitors in Older Adults.

Elias R, Morales J, Rehman Y, Khurshid H.

Curr Oncol Rep. 2016 Aug;18(8):47. doi: 10.1007/s11912-016-0534-9. Review.

PMID:
27287329
20.

Practical designs for Phase I combination studies in oncology.

Wages NA, Ivanova A, Marchenko O.

J Biopharm Stat. 2016;26(1):150-66. doi: 10.1080/10543406.2015.1092029. Review.

Supplemental Content

Support Center